- Cellectis ( NASDAQ: CLLS ) on Thursday launched a global offering of USD22 million of its American Depositary Shares.
- Shares -17.2% at $2.70 after the bell.
- The underwriting agreement is expected to be entered into by Cellectis, Jefferies and Barclays Capital.
- The global offering is comprised of a public offering of ADS in the U.S. only, and a private placement in other countries, including in European Union member states.
- The company plans to use the net proceeds of the offering to fund the continued clinical development of UCART123, UCART22, UCART20x22, and UCARTCS1, and for working capital and other general corporate purposes.
For further details see:
Cellectis stock plunges ~17% after hours on $22M ADS offering